See Cleerly.
Act early.
Cleerly’s AI-enabled CCTA solution provides comprehensive, accurate, and trackable insights to personalize heart attack prevention.
See the Cleerly DifferenceCREDENCE Trial
In the prospective, multicenter CREDENCE trial, Cleerly ISCHEMIA demonstrated higher diagnostic accuracy and area under the curve compared to FFRCT and stress testing, as referenced to 868 invasive measurements by fractional flow reserve (FFR), the ‘gold standard’ for determining ischemia.2
PACIFIC Trial
In a post-hoc analysis of the PACIFIC study, Cleerly ISCHEMIA was compared to FFRCT, 15O-H2O PET and SPECT to predict invasive FFR≤0.8 as reference standard. On a per-patient basis Cleerly ISCHEMIA, FFRCT and PET performed similarly and outperformed SPECT in predicting ischemia.2 Cleerly ISCHEMIA, using multivariate analysis, was the only non-invasive ischemia test that was prognostic of future MACE events, FFRCT and SPECT were not.2
What is Cleerly?
Cleerly is a comprehensive, AI-driven platform that quantifies and assesses coronary artery disease (CAD) to deliver clinically actionable insights through a web-based solution. Our software quantifies atherosclerosis by measuring plaque volume, composition, length, and location, evaluates stenosis severity in both 2D (diameter and area) and 3D (lumen and vessel volume), with a workflow for determining the likely presence or absence of ischemia, potentially reducing the need for additional testing and enhancing diagnostic confidence.
Explore Our TechnologySee more of what matters
Schedule a one-on-one product demo to see the benefits of Cleerly for your patients & practice.





